CIBC Asset Management Inc acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the fourth quarter, Holdings Channel reports. The firm acquired 2,966 shares of the company’s stock, valued at approximately $230,000.

Other hedge funds also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company boosted its position in Neurocrine Biosciences by 7.8% during the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after purchasing an additional 193 shares during the period. Crow Point Partners LLC bought a new position in Neurocrine Biosciences during the fourth quarter worth $145,000. Comerica Bank bought a new position in Neurocrine Biosciences during the third quarter worth $210,000. Ardsley Advisory Partners bought a new position in Neurocrine Biosciences during the second quarter worth $230,000. Finally, Cubist Systematic Strategies LLC boosted its position in Neurocrine Biosciences by 151.5% during the second quarter. Cubist Systematic Strategies LLC now owns 5,301 shares of the company’s stock worth $244,000 after purchasing an additional 3,193 shares during the period.

In related news, Director William H. Rastetter sold 9,500 shares of the company’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $90.00, for a total transaction of $855,000.00. Following the completion of the sale, the director now owns 34,250 shares of the company’s stock, valued at $3,082,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gary A. Lyons sold 10,000 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $72.92, for a total transaction of $729,200.00. Following the sale, the director now directly owns 272,066 shares of the company’s stock, valued at approximately $19,839,052.72. The disclosure for this sale can be found here. In the last three months, insiders sold 337,950 shares of company stock valued at $26,613,876. 4.80% of the stock is currently owned by company insiders.

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) opened at $85.38 on Thursday. The stock has a market cap of $7,560.00, a PE ratio of -38.46, a PEG ratio of 6.41 and a beta of 0.26. Neurocrine Biosciences, Inc. has a 52-week low of $39.21 and a 52-week high of $91.82. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Tuesday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.11). The firm had revenue of $94.52 million for the quarter, compared to the consensus estimate of $94.00 million. During the same period in the previous year, the firm posted ($0.51) earnings per share. sell-side analysts forecast that Neurocrine Biosciences, Inc. will post -1.48 EPS for the current year.

A number of equities analysts have commented on NBIX shares. Piper Jaffray Companies reaffirmed a “buy” rating and set a $76.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, October 25th. Citigroup reaffirmed a “buy” rating and set a $79.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Leerink Swann reaffirmed an “outperform” rating and set a $83.00 price objective (up from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. BMO Capital Markets lifted their price objective on shares of Neurocrine Biosciences from $83.00 to $109.00 and gave the stock an “outperform” rating in a research report on Thursday, November 2nd. Finally, Deutsche Bank reaffirmed a “buy” rating and set a $79.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. One equities research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $89.53.

TRADEMARK VIOLATION NOTICE: “CIBC Asset Management Inc Acquires Shares of 2,966 Neurocrine Biosciences, Inc. (NBIX)” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://theolympiareport.com/2018/02/15/cibc-asset-management-inc-acquires-shares-of-2966-neurocrine-biosciences-inc-nbix.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.